AffyImmune Therapeutics

Affy Immune Therapeutics

Biotechnology, 22 Strathmore Rd, Natick, Massachusetts, 01760, United States, 11-50 Employees

affyimmune.com

  • twitter
  • LinkedIn

phone no Phone Number: 15*********

Who is AFFYIMMUNE THERAPEUTICS

Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first produ...

Read More

map
  • 22 Strathmore Rd, Natick, Massachusetts, 01760, United States Headquarters: 22 Strathmore Rd, Natick, Massachusetts, 01760, United States
  • 2016 Date Founded: 2016
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731

checked-icon Does something look wrong? Fix it. | View contact records from AFFYIMMUNE THERAPEUTICS

AffyImmune Therapeutics Org Chart and Mapping

Employees

Dawn Buchanan

Vice President Clinical Operations

Srinija Alla

Senior Research Associate- R&D Project Management

Eric Dunn

Cmc Logistics Manager

Karrie Du

Senior Cmc Associate

Aishwarya Raghuraman

Cmc Associate, Analytical Development

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding AffyImmune Therapeutics

Answer: AffyImmune Therapeutics's headquarters are located at 22 Strathmore Rd, Natick, Massachusetts, 01760, United States

Answer: AffyImmune Therapeutics's phone number is 15*********

Answer: AffyImmune Therapeutics's official website is https://affyimmune.com

Answer: AffyImmune Therapeutics's revenue is $1 Million to $5 Million

Answer: AffyImmune Therapeutics's SIC: 8731

Answer: AffyImmune Therapeutics has 11-50 employees

Answer: AffyImmune Therapeutics is in Biotechnology

Answer: AffyImmune Therapeutics contact info: Phone number: 15********* Website: https://affyimmune.com

Answer: Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first product, spares healthy cells through our unique affinity-tuning, enhancing its safety and efficacy. The initial indication for AIC100 is refractory thyroid cancer, which has a very poor prognosis and very few effective therapies. The antigen targeted by AIC100 is also overexpressed in a variety of additional cancers, including stomach, triple negative breast cancer and a number of others.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access